Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma

Assiut University

Status: Unknown

Conditions: Hepatocellular Carcinoma

Treatments: Other: LDH serum level

Study type: Observational

Funder types: Other

Identifiers

NCT03338166

URL

Details and patient eligibility

About

Hepatocellular carcinoma represents the commonest primary cancer of the liver.serum lactate dehydrogenase is an indirect marker of tumor hypoxia,angioneogenesis and worse prognosis.

Full description

Hepatocellular carcinoma (HCC) represents the commonest primary cancer of the liver. Incidence is increasing and HCC has risen to become the 5th commonest malignancy worldwide and the third leading cause of cancer related death, exceeded only by cancers of the lung and stomach. HCC prevalence is higher in sub-Saharan Africa, central and Southeast Asia.Serum lactate dehydrogenase (LDH) levels is an indirect marker of tumor hypoxia, angioneogenesis and worse prognosis. Lactic dehydrogenase (LDH), which is a glycolytic enzyme, composed of four polypeptide chains, each one encoded by separate gene (M and H), exists in various types of human tissue and neoplasms. LDH is a key enzyme in the conversion pyruvate to lactate under anaerobic conditions .Five isoforms of LDH have been identified as a result of the five different combinations of polypeptide subunits.

Hypoxia represents a clinical biological mechanism for treatment resistance in cancer cells via the formation of new blood vessels. Furthermore, a growing body of evidence indicates that hypoxia might actually promote cancer development.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with Hepatocellular carcinoma diagnosed by biopsy or imaging criteria and alpha feto protein.
• signed informed consent before registration in study
• Eastern Cooperative oncology Groups Performance status between 0 and 2.

Exclusion criteria

• Cachexia or poor condition
• pregnant or human chorionic gonadotropin positive
• patient with another liver tumor
• Any previous treatment

Trial design

50 participants in 4 patient groups

Group A

Description:

Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment

Treatment:

Other: LDH serum level

Group B

Description:

Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment

Treatment:

Other: LDH serum level

Group C

Description:

Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment

Treatment:

Other: LDH serum level

Group D

Description:

Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months

Treatment:

Other: LDH serum level